Mirada Medical, a medical imaging company based in the U.K., has received FDA approval for its Simplicit90Y dosimetry software.
The solution, developed as part of a collaboration with BTG Interventional Oncology, was designed to help specialists provide personalized treatment to liver cancer patients and improve Y90 Transarterial Radioembolization (TARE) workflow. With Simplicit90Y, users are able to display, process and report key dosimetry data.
“Mirada has leveraged its advanced medical image processing tools to provide a software for improving consistency and efficiency in the Y90 TARE workflow,” Sarah Bond, vice president of product management for Mirada Medical, said in a prepared statement. “We are delighted to be able to offer Simplicit90Y workflows for planning and post-treatment Y90 dosimetry to US physicians.”
The Simplicit90Y software has already received CE Mark certification and is approved to be used in Canada, according to the Mirada Medical statement.